Email: cspc@cspc.cn
Media
News Center
Jan. 20
2023
Highly Selective Prmt5 Inhibitor SYH2045 Obtains Clinical Trial Approval
Jan. 19
Octreotide Long-Acting Injection Obtains Clinical Trial Approval
Jan. 09
levidipine Injectable Emulsion Obtains Clinical Approval
Jan. 05
Meloxicam Nanocrystal Injection Obtains Clinical Trial Approval
Dec. 14
2022
CSPC's Innovative Drug Research Results Selected for the 2022 ASH Annual Meeting
The American Society of Hematology (ASH) Annual Meeting will be held in New Orleans, USA, December 10~13, 2022. As the world's largest professional society on the etiology and treatment of blood disorders, the ASH Annual Meeting is one of the largest and most comprehensive international academic events in the field of hematology worldwide.
Dec. 07
Oral Small-Molecule 3CLpro Inhibitor SYH2055 Against SAR-CoV-2 Obtains Clinical Trial Approval
Contact Us
Phone:
+86 311 6780 9955
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
